Sai Life Sciences is a global Contract Research, Development and Manufacturing Organization (CRDMO) that partners with pharmaceutical and biotechnology companies across the drug development lifecycle. Supporting more than 300 innovator companies across the US, UK, Europe and Japan, the company provides integrated scientific capabilities spanning early drug discovery, development and commercial manufacturing.
Its global network includes integrated R&D campuses and commercial manufacturing facilities in India, a Discovery Biology site in Boston, USA, and a Process R&D laboratory at Alderley Park in the UK. These facilities bring together expertise across drug discovery, process development, analytical sciences and manufacturing, enabling multidisciplinary teams to support customer programs from early research through commercial supply.
With a team of over 3,800 scientists and professionals across India, the UK and the US, Sai Life Sciences supports both individual scientific services and integrated programs, with multidisciplinary teams collaborating across the drug development lifecycle.
Integrated Drug Discovery
Sai Life Sciences offers integrated drug discovery capabilities that support programs from target identification and hit discovery through lead optimization and candidate selection. Its scientific expertise spans medicinal chemistry, computational chemistry, structural biology, in vitro biology, DMPK, exploratory toxicology, pharmaceutical development and compound management.
These capabilities are brought together through integrated Design-Make-Test-Analyze (DMTA) workflows, enabling scientists to work collaboratively throughout the discovery process. Data generated across multiple disciplines is continuously integrated to guide molecular design, optimize lead compounds and support informed scientific decision-making.
The company supports a range of engagement models, from standalone scientific services to dedicated multidisciplinary teams that function as an extension of customer R&D organizations. This flexibility enables customers to access specialized expertise while benefiting from coordinated scientific execution across discovery programs.
Development and Manufacturing
As molecules advance beyond discovery, Sai Life Sciences provides integrated Chemistry, Manufacturing and Controls (CMC) capabilities that support progression into clinical development and commercial manufacturing. Services include discovery process chemistry, process development, analytical development, particle science and engineering, formulation development, clinical trial material manufacturing and regulatory support.
Commercial manufacturing capabilities include the production of active pharmaceutical ingredients (APIs) and advanced intermediates through manufacturing facilities with an installed capacity exceeding 700 KL. Manufacturing operations are supported by established quality systems, digital manufacturing technologies and operational excellence practices designed to support reliable scale-up and compliance with global regulatory expectations.
By providing discovery, development and manufacturing capabilities within a single organization, Sai Life Sciences enables programs to transition between stages while maintaining scientific continuity and operational alignment.
Scientific and Technology Differentiators
Sai Life Sciences continues to invest in scientific capabilities and technologies that support evolving drug discovery and development needs.
The company is expanding expertise in emerging therapeutic modalities, including peptides, antibody-drug conjugates (ADCs), oligonucleotides, lipids and targeted protein degraders, enabling customers to pursue increasingly diverse therapeutic approaches alongside traditional small molecule programs.
Technology investments include AI-enabled scientific workflows, laboratory automation, high-throughput experimentation (HTE), commercial-scale photo flow chemistry, computational tools and advanced analytical platforms. These capabilities support data-driven decision-making, improve process understanding and enhance productivity across discovery and development.
An integrated organizational structure further differentiates the company by bringing together discovery scientists, process chemists, analytical scientists and manufacturing teams within a connected operating model. Early collaboration across functions facilitates knowledge sharing throughout the molecule lifecycle and supports efficient progression from research to commercial supply.
Enabling Drug Development Through Integration
Drug development increasingly requires close coordination across scientific disciplines, technologies and development stages. Sai Life Sciences supports this need through an integrated CRDMO model that connects discovery, development and manufacturing within a single organization.
This approach provides customers with the flexibility to engage at any stage of the drug development lifecycle while maintaining continuity as programs evolve. Multidisciplinary scientific teams work together to address challenges across chemistry, biology, process development and manufacturing, reducing operational complexity and enabling informed decision-making throughout the lifecycle of a molecule.
Today, Sai Life Sciences supports more than 300 pharmaceutical and biotechnology companies worldwide, including 19 of the world's top 25 pharmaceutical companies. By combining integrated scientific capabilities, investments in advanced technologies and expertise across discovery, development and manufacturing, the company provides a connected framework for advancing drug candidates from early research through commercial production.
About Drug Discovery Innovation Programme 2026
The Drug Discovery Innovation Programme, organized by World BI, is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2026 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.